BDF
GRCE

Balasa Dinverno & Foltz’s Grace Therapeutics GRCE Stock Holding History

Balasa Dinverno & Foltz’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-448
Closed -$8K – 287
2020
Q1 		$8K Buy
448
+188
+72% +$6.66K ﹤0.01% 249
2019
Q4 		$31K Buy
+260
New +$25.7K ﹤0.01% 267

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JLBC
J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Balasa Dinverno & Foltz's GRCE Position: Q2 2020 in Review

Balasa Dinverno & Foltz sold out of Grace Therapeutics (GRCE) in Q2 2020, closing a stake of 448 shares — an estimated $8K sold.

Balasa Dinverno & Foltz first reported a position in GRCE in Q4 2019 and held it in 2 quarters. The position peaked at $31K in Q4 2019. 25 funds tracked by Wall St. Rank hold GRCE as of Q2 2020.

  • Balasa Dinverno & Foltz reported no remaining Grace Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Balasa Dinverno & Foltz sold 448 Grace Therapeutics shares in Q2 2020, an estimated $8K.
  • Balasa Dinverno & Foltz first reported a position in Grace Therapeutics in Q4 2019 and held it in 2 quarters.
  • Balasa Dinverno & Foltz's Grace Therapeutics position peaked at $31K in Q4 2019.
  • 25 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2020.

Based on Balasa Dinverno & Foltz's 13F filing for Q2 2020, filed 7 Aug 2020.